{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T23:20:33Z","timestamp":1795044033952,"version":"4.10.2"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"DOI":"10.1208\/s12248-026-01292-1","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T19:39:43Z","timestamp":1790105983000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Challenges in the Quantification of Free TFPI in Human Plasma Following Marstacimab Treatment"],"prefix":"10.1208","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6897-4274","authenticated-orcid":false,"given":"Katherine","family":"Wright","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6199-8378","authenticated-orcid":false,"given":"Kerry","family":"Kelleher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9206-6880","authenticated-orcid":false,"given":"Parya","family":"Nouri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3749-1522","authenticated-orcid":false,"given":"Lindsay","family":"King","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8476-5427","authenticated-orcid":false,"given":"Hendrik","family":"Neubert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"},{"role":"corresponding-author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"1292_CR1","doi-asserted-by":"crossref","unstructured":"Zimmerman B, Valentino LA. Hemophilia: in review. Pediatr Rev. 2013;34(7):289\u201394; quiz 95.","DOI":"10.1542\/pir.34.7.289"},{"issue":"Suppl 1","key":"1292_CR2","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1097\/00001721-199506001-00002","volume":"6","author":"GJ Broze Jr.","year":"1995","unstructured":"Broze GJ Jr. Tissue factor pathway inhibitor and the current concept of blood coagulation. Blood Coagul Fibrinolysis. 1995;6(Suppl 1):S7-13.","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"4","key":"1292_CR3","first-page":"551","volume":"5","author":"GJ Broze Jr","year":"1994","unstructured":"Broze GJ Jr, Lange GW, Duffin KL, MacPhail L. Heterogeneity of plasma tissue factor pathway inhibitor. Blood Coagul Fibrinolysis. 1994;5(4):551\u20139.","journal-title":"Blood Coagul Fibrinolysis."},{"issue":"44","key":"1292_CR4","doi-asserted-by":"publisher","first-page":"17838","DOI":"10.1073\/pnas.1310444110","volume":"110","author":"JP Wood","year":"2013","unstructured":"Wood JP, Bunce MW, Maroney SA, Tracy PB, Camire RM, Mast AE. Tissue factor pathway inhibitor-alpha inhibits prothrombinase during the initiation of blood coagulation. Proc Natl Acad Sci U S A. 2013;110(44):17838\u201343.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1292_CR5","doi-asserted-by":"crossref","unstructured":"Mast AE, Ruf W. Regulation of coagulation by tissue factor pathway inhibitor: implications for hemophilia therapy. J Thromb Haemost. 2022;20(6):1290\u20131300.","DOI":"10.1111\/jth.15697"},{"issue":"19","key":"1292_CR6","doi-asserted-by":"publisher","first-page":"2934","DOI":"10.1182\/blood-2013-11-512764","volume":"123","author":"JP Wood","year":"2014","unstructured":"Wood JP, Ellery PE, Maroney SA, Mast AE. Biology of tissue factor pathway inhibitor. Blood. 2014;123(19):2934\u201343.","journal-title":"Blood"},{"issue":"4","key":"1292_CR7","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1055\/s-0038-1646439","volume":"66","author":"O Nordfang","year":"1991","unstructured":"Nordfang O, Valentin S, Beck TC, Hedner U. Inhibition of extrinsic pathway inhibitor shortens the coagulation time of normal plasma and of hemophilia plasma. Thromb Haemost. 1991;66(4):464\u20137.","journal-title":"Thromb Haemost"},{"issue":"2","key":"1292_CR8","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/0049-3848(91)90120-L","volume":"64","author":"DJ Welsch","year":"1991","unstructured":"Welsch DJ, Novotny WF, Wun TC. Effect of lipoprotein-associated coagulation inhibitor (LACI) on thromboplastin-induced coagulation of normal and hemophiliac plasmas. Thromb Res. 1991;64(2):213\u201322.","journal-title":"Thromb Res"},{"issue":"19","key":"1292_CR9","doi-asserted-by":"publisher","first-page":"7623","DOI":"10.1073\/pnas.87.19.7623","volume":"87","author":"D Repke","year":"1990","unstructured":"Repke D, Gemmell CH, Guha A, Turitto VT, Broze GJ Jr, Nemerson Y. Hemophilia as a defect of the tissue factor pathway of blood coagulation: effect of factors VIII and IX on factor X activation in a continuous-flow reactor. Proc Natl Acad Sci U S A. 1990;87(19):7623\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"1292_CR10","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1111\/jth.14207","volume":"16","author":"M Cardinal","year":"2018","unstructured":"Cardinal M, Kantaridis C, Zhu T, Sun P, Pittman DD, Murphy JE, et al. A first-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06741086, an anti-tissue factor pathway inhibitor mAb, in healthy volunteers. J Thromb Haemost. 2018;16(9):1722\u201331.","journal-title":"J Thromb Haemost"},{"issue":"suppl 1","key":"1292_CR11","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2019-130327","volume":"134","author":"C Parng","year":"2019","unstructured":"Parng C, Jin M, Holsti M, Benard S, Rakhe S, Patel-Hett SR, et al. In vitro and in vivo characterization of marstacimab, an anti-TFPI antibody. Blood. 2019;134(suppl 1):2391.","journal-title":"Blood."},{"issue":"2","key":"1292_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12679","volume":"6","author":"DD Pittman","year":"2022","unstructured":"Pittman DD, Rakhe S, Bowley SR, Jasuja R, Barakat A, Murphy JE. Hemostatic efficacy of marstacimab alone or in combination with bypassing agents in hemophilia plasmas and a mouse bleeding model. Res Pract Thromb Haemost. 2022;6(2):e12679.","journal-title":"Res Pract Thromb Haemost"},{"key":"1292_CR13","unstructured":"US Food and Drug Administration. Hympavzi (marstacimab-hncq). Prescribing information. 2026. [Cited 2026 August]. Available from: https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=20916."},{"key":"1292_CR14","unstructured":"European Medicines Agency. Hympavzi (marstacimab). Summary of product characteristics. 2026 [Cited 2026 August]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/variation\/hympavzi."},{"issue":"6","key":"1292_CR15","doi-asserted-by":"publisher","first-page":"659","DOI":"10.4155\/bio.11.28","volume":"3","author":"LK Roskos","year":"2011","unstructured":"Roskos LK, Schneider A, Vainshtein I, Schwickart M, Lee R, Lu H, et al. PK-PD modeling of protein drugs: implications in assay development. Bioanalysis. 2011;3(6):659\u201375.","journal-title":"Bioanalysis"},{"issue":"3","key":"1292_CR16","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/j.1742-7843.2009.00513.x","volume":"106","author":"PJ Lowe","year":"2010","unstructured":"Lowe PJ, Tannenbaum S, Wu K, Lloyd P, Sims J. On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models. Basic Clin Pharmacol Toxicol. 2010;106(3):195\u2013209.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"2","key":"1292_CR17","doi-asserted-by":"publisher","first-page":"288","DOI":"10.4161\/mabs.23508","volume":"5","author":"RJ Hansen","year":"2013","unstructured":"Hansen RJ, Brown RM, Lu J, Wroblewski VJ. Qualification of a free ligand assay in the presence of anti-ligand antibody Fab fragments. MAbs. 2013;5(2):288\u201396.","journal-title":"MAbs"},{"issue":"1","key":"1292_CR18","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1208\/s12248-011-9251-3","volume":"13","author":"JW Lee","year":"2011","unstructured":"Lee JW, Kelley M, King LE, Yang J, Salimi-Moosavi H, Tang MT, et al. Bioanalytical approaches to quantify \u201ctotal\u201d and \u201cfree\u201d therapeutic antibodies and their targets: technical challenges and PK\/PD applications over the course of drug development. AAPS J. 2011;13(1):99\u2013110.","journal-title":"AAPS J"},{"issue":"20","key":"1292_CR19","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.4155\/bio-2017-0152","volume":"9","author":"H Zhang","year":"2017","unstructured":"Zhang H, Gu H, Shipkova P, Ciccimaro E, Sun H, Zhao Q, et al. Immunoaffinity LC-MS\/MS for quantitative determination of a free and total protein target as a target engagement biomarker. Bioanalysis. 2017;9(20):1573\u201388.","journal-title":"Bioanalysis."},{"issue":"20","key":"1292_CR20","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.4155\/bio.12.220","volume":"4","author":"JW Lee","year":"2012","unstructured":"Lee JW, Salimi-Moosavi H. Bioanalysis of target biomarker and PK\/PD relevancy during the development of biotherapeutics. Bioanalysis. 2012;4(20):2513\u201323.","journal-title":"Bioanalysis"},{"issue":"1","key":"1292_CR21","doi-asserted-by":"publisher","first-page":"262","DOI":"10.2741\/3926","volume":"17","author":"GJ Broze Jr","year":"2012","unstructured":"Broze GJ Jr, Girard TJ. Tissue factor pathway inhibitor: structure-function. Front Biosci (Landmark Ed). 2012;17(1):262\u201380.","journal-title":"Front Biosci (Landmark Ed)."},{"issue":"7","key":"1292_CR22","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1016\/j.xphs.2018.03.010","volume":"107","author":"C Parng","year":"2018","unstructured":"Parng C, Singh P, Pittman DD, Wright K, Leary B, Patel-Hett S, et al. Translational pharmacokinetic\/pharmacodynamic characterization and target-mediated drug disposition modeling of an anti-tissue factor pathway inhibitor antibody, PF-06741086. J Pharm Sci. 2018;107(7):1995\u20132004.","journal-title":"J Pharm Sci"},{"issue":"5","key":"1292_CR23","doi-asserted-by":"publisher","first-page":"576","DOI":"10.4161\/mabs.2.5.12833","volume":"2","author":"JP Davda","year":"2010","unstructured":"Davda JP, Hansen RJ. Properties of a general PK\/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets. MAbs. 2010;2(5):576\u201388.","journal-title":"MAbs"},{"issue":"1","key":"1292_CR24","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ab.2013.05.012","volume":"440","author":"ES Day","year":"2013","unstructured":"Day ES, Capili AD, Borysenko CW, Zafari M, Whitty A. Determining the affinity and stoichiometry of interactions between unmodified proteins in solution using Biacore. Anal Biochem. 2013;440(1):96\u2013107.","journal-title":"Anal Biochem"},{"key":"1292_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ab.2023.115263","volume":"679","author":"K Nguyen","year":"2023","unstructured":"Nguyen K, Li K, Flores K, Tomaras GD, Dennison SM, McCarthy JM. Parameter estimation and identifiability analysis for a bivalent analyte model of monoclonal antibody-antigen binding. Anal Biochem. 2023;679:115263.","journal-title":"Anal Biochem"},{"issue":"23","key":"1292_CR26","doi-asserted-by":"publisher","first-page":"4672","DOI":"10.1182\/blood.V126.23.4672.4672","volume":"126","author":"J-M Gu","year":"2015","unstructured":"Gu J-M, Patel C, Kauser K. Plasma tissue factor pathway inhibitor (TFPI) levels in healthy subjects and patients with hemophilia A and B. Blood. 2015;126(23):4672.","journal-title":"Blood"},{"issue":"12","key":"1292_CR27","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1136\/ard.60.12.1149","volume":"60","author":"I Ertenli","year":"2001","unstructured":"Ertenli I, Kiraz S, Celik IC, Haznedaroglu C, Erman M, Calg\u00fcneri M, et al. Changes in the concentration and distribution of tissue factor pathway inhibitor in Behcet\u2019s disease and systemic lupus erythematosus: effect on the prethrombotic state. Ann Rheum Dis. 2001;60(12):1149\u201351.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1292_CR28","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1111\/hae.13820","volume":"25","author":"S Patel-Hett","year":"2019","unstructured":"Patel-Hett S, Martin EJ, Mohammed BM, Rakhe S, Sun P, Barrett JC, et al. Marstacimab, a tissue factor pathway inhibitor neutralizing antibody, improves coagulation parameters of ex vivo dosed haemophilic blood and plasmas. Haemophilia. 2019;25(5):797\u2013806.","journal-title":"Haemophilia"},{"issue":"2","key":"1292_CR29","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1208\/s12248-015-9855-0","volume":"18","author":"AP Mayer","year":"2016","unstructured":"Mayer AP, Hottenstein CS. Ligand-binding assay development: what do you want to measure versus what you are measuring. AAPS J. 2016;18(2):287\u20139.","journal-title":"AAPS J"},{"issue":"suppl 3","key":"1292_CR30","first-page":"S75","volume":"55","author":"S Zheng","year":"2015","unstructured":"Zheng S, McIntosh T, Wang W. Utility of free and total target measurements as target engagement and efficacy biomarkers in biotherapeutic development\u2014opportunities and challenges. J Clin Pharmacol. 2015;55(suppl 3):S75-84.","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"1292_CR31","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.thromres.2012.08.299","volume":"130","author":"M Gissel","year":"2012","unstructured":"Gissel M, Orfeo T, Foley JH, Butenas S. Effect of BAX499 aptamer on tissue factor pathway inhibitor function and thrombin generation in models of hemophilia. Thromb Res. 2012;130(6):948\u201355.","journal-title":"Thromb Res"},{"issue":"23","key":"1292_CR32","doi-asserted-by":"publisher","first-page":"3513","DOI":"10.1182\/blood.V126.23.3513.3513","volume":"126","author":"M Bauzon","year":"2015","unstructured":"Bauzon M, Liu B, Grudzinska-Goebel J, Tebbe J, Pan J, Cifrese J, et al. Characterization of a high-affinity fully human IgG2 antibody against tissue factor pathway inhibitor as a bypass agent for the treatment of hemophilia. Blood. 2015;126(23):3513.","journal-title":"Blood."},{"issue":"5","key":"1292_CR33","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1111\/jth.12864","volume":"13","author":"P Chowdary","year":"2015","unstructured":"Chowdary P, Lethagen S, Friedrich U, Brand B, Hay C, Abdul Karim F, et al. Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial. J Thromb Haemost. 2015;13(5):743\u201354.","journal-title":"J Thromb Haemost."},{"issue":"11","key":"1292_CR34","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1111\/jth.14272","volume":"16","author":"H Eichler","year":"2018","unstructured":"Eichler H, Angchaisuksiri P, Kavakli K, Knoebl P, Windyga J, Jim\u00e9nez-Yuste V, et al. A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A. J Thromb Haemost. 2018;16(11):2184\u201395.","journal-title":"J Thromb Haemost"},{"issue":"4","key":"1292_CR35","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1208\/s12248-017-0086-4","volume":"19","author":"J-M Gu","year":"2017","unstructured":"Gu J-M, Zhao X-Y, Schwarz T, Schuhmacher J, Baumann A, Ho E, et al. Mechanistic modeling of the pharmacodynamic and pharmacokinetic relationship of tissue factor pathway inhibitor-neutralizing antibody (BAY 1093884) in cynomolgus monkeys. AAPS J. 2017;19(4):1186\u201395.","journal-title":"AAPS J."},{"issue":"suppl 1","key":"1292_CR36","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1182\/blood-2018-99-114683","volume":"132","author":"P Chowdary","year":"2018","unstructured":"Chowdary P, Lissitchkov TJ, Willmann S, Schwers S, Michaels LA, Shah A. Pharmacodynamics, pharmacokinetics and safety of Bay 1093884, an antibody directed against human TFPI, in patients with factor VIII or IX deficiency (with and without inhibitors): a phase 1 study. Blood. 2018;132(suppl 1):1176.","journal-title":"Blood"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01292-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-026-01292-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01292-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T23:14:49Z","timestamp":1795043689000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-026-01292-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":36,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["1292"],"URL":"https:\/\/doi.org\/10.1208\/s12248-026-01292-1","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"assertion":[{"value":"20 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing financial interests: KW, KK, PN, LK, and HN are employees and shareholders of Pfizer.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"161"}}